Gentium price target raised to $60 from $38 at Brean Capital Brean Capital raised Gentium's price target to $60 following the EMA approval of Defibrotide.
http://www.theflyonthewall.com/permalinks/entry.php/GENTid1904136/GENT-Gentium-price-target-raised-to--from--at-Brean-Capital
http://www.theflyonthewall.com/permalinks/entry.php/GENTid1904136/GENT-Gentium-price-target-raised-to--from--at-Brean-Capital
No comments:
Post a Comment